Glitazones and pancreatic function;Glitazones et fonction pancréatique

Annales d'Endocrinologie

Volumn 66, Issue 2 II, 2005, Pages

  Girard, J ^a  

^a INSTITUT COCHIN   (France)

Author keywords

Animal studies; Fatty acid; Pancreatic cell; PPAR receptors; Rosiglitazone; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE; LIGAND; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

APOPTOSIS; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS SECRETION; PATHOGENESIS; RAT STRAIN; REVIEW; SKELETAL MUSCLE; ZUCKER DIABETIC FATTY RAT;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; THIAZOLIDINEDIONES;

EID: 17744372534     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. De Fronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-68.
2. Ferrannini E. Insulinresistance vs insulin deficiency in non-insulin dependant diabetes melitus: problems and prospects. Endocr Rev 1998; 19: 477-90.
3. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
4. Vialettes B, Valéro R. Les stades précoces du déficit bêta-pancréatique: la « chronique d'un diabète annoncé ». Diabetes Metab 2003; 29: 3S11-3S15.
5. Portha B, Movassat J, Plachot C, Saulnier C. Anomalies de la croissance et du potentiel régénératif des cellules β-pancréatique chez le rat GK, modèle de DNID. In « Journées de Diabétologie. Hôtel-Dieu 1999 ». Médecine-Sciences. Flammarion. Paris. 1999. pp 25-38.
6. Girard J. Cellule β-pancréatique, glitazones et diabète de type 2. Masson Thérapeutique Diabétologie. 2003; ACB/018 (8 pages).
7. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58.
8. Holman RR. Assessing the potential for alpha-glucosidases inhibitors in prediabetic states. Diabetes Res Clin Pract 1998; 40(Suppl.): 521-525.
9. UK Prospective Diabetes Study (UKPDS) Group. UKPDS 26. Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 1998; 15: 297-303.
10. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004; 47: 31-9.
11. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-8.
12. Bennett SMA, Agrawal A, Elasha H, et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 2004; 21: 415-22.
13. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172-8.
14. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992; 18: 415-31.
15. Kahn SE. The importance of β cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 4047-58.
16. Linger RH. Lipotoxicity in the pathogenesis of obesity-dependant NIDDM. Genetic and clinical implications. Diabetes 1995; 44: 863-70.
17. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 128-38.
18. Girard J. Rôle des acides gras libres dans l'insulinoré sistance au cours du diabète non insulinodépendant. Diabetes Metab 2000; 21: 79-88.
19. Girard J. Acide gras et cellule β. Diabetes Metab 2000; 26: 6-9.
20. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998; 95: 2498-502.
21. Poitout V, Briaud I, Kelpe C, Hagman D. Gluco-lipotoxicité of the pancreatic beta cell. Ann Endocrinol 2004; 65: 37-41.
22. Dubois M, Pattou F, Kerr-Conte J, et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000; 43: 1165-9.
23. Buckingham RE, Al-Barazanji KA, Toseland CDN, et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker Fatty rats. Diabetes 1998; 47: 1326-34.
24. Finegood DT, McArthur MD, Kojwang D, et al. β-cell mass dynamics in Zucker Diabetic Fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-9.
25. Benkoczi CL, Topp BG, Finegood DT. Rosiglitazone has a greater insulin sensitizing action in pre-diabetic than incipiently Zucker Diabetic Fatty rats. Diabetes 2002; 51 (Suppl. 2): A136 [abstract 551-P].
26. Smith SA, Lister CA, Toseland CD, Buckingham RE. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker Diabetic Fatty rat. Diabetes Obes Metab 2000; 2: 363-72.
27. Girard J. Effet antidiabétique des thiazolidinediones In « Journée de Diabétologie. Hôtel-Dieu 2007 ». Flammarion. Medecine-Sciences. Paris. 2001. pp. 33-45.
28. Unger RH. How obesity causes diabetes in Zucker Diabetic Fatty rats. Trends Endocrinol Metab 1997; 8: 276-82.
29. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta-cell function of Zucker Diabetic Fatty rats. J Biol Chem 1998; 273: 3547-50.
30. Higa M, Zhou YT, Ravazzola M, et al. Troglitazone prevents mitochondrial alterations, β-cell destruction, and diabetes in obese pre-diabetic rats. Proc Natl Acad Sci USA 1999; 96: 11513-8.
31. Pégorier JP, Girard J. Thiazolidinediones et insulinosensibilité: rôle du récepteur nucléaire PPARγ. Ann Endocrinol 2004; 65: 65-72.
32. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6.
33. Lebovitz HE. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am J Cardiol 2002; 90 (suppl.): 34G-41G.
34. Blicklé JF. Place des thiazolidinediones dans le traitement du diabète de type 2. Presse Med 2004; 33: 1034-40.